Question 1

What is OKYO Pharma?

Accepted Answer

OKYO Pharma is a Company.

Question 2

How often does OKYO Pharma appear in global news?

Accepted Answer

Tracked across 4 news events drawn from 44 articles.

Question 3

When was OKYO Pharma first tracked by Ergen?

Accepted Answer

First tracked on May 19, 2026.

Question 4

When was OKYO Pharma last mentioned in news?

Accepted Answer

Last active on Jul 23, 2026.

Question 5

What is OKYO Pharma's current news sentiment?

Accepted Answer

Aggregate sentiment score: 25 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is OKYO Pharma in global news coverage?

Accepted Answer

Attention score of 2, derived from article volume and coverage intensity across 4 events.

Question 7

What is the most recent event involving OKYO Pharma?

Accepted Answer

OKYO_Pharma appoints Marta_Sacchetti to SAB (May 19, 2026, 7 articles).

Question 8

Who is OKYO Pharma most connected to?

Accepted Answer

Top relationships: Flavio Mantelli, Flavio Mantelli (chief medical officer).

Question 9

How did the "OKYO_Pharma appoints Marta_Sacchetti to SAB" event impact OKYO Pharma?

Accepted Answer

OKYO Pharma>>> expanded its Scientific Advisory Board with the appointment of Marta Sacchetti>>> to strengthen its expertise in neuro-inflammatory corneal diseases and advance its clinical programs for Urgoskin.

Question 10

How did the "OKYO Pharma at Piper Sandler Symposium" event impact OKYO Pharma?

Accepted Answer

OKYO Pharma is the subject of the announcement, participating in the symposium to present its clinical developments.

Question 11

How did the "OKYO Pharma FDA Type D meeting positive" event impact OKYO Pharma?

Accepted Answer

OKYO Pharma received positive FDA feedback validating its clinical path for urcosimod, de-risking the program and supporting advancement into a global Phase 3 trial. This milestone could enhance the company's valuation and prospects.

Question 12

How did the "OKYO Pharma insider share purchases" event impact OKYO Pharma?

Accepted Answer

OKYO Pharma is the subject of insider buying, indicating management confidence. The company is preparing for a Phase 3 trial of urcosimod for NCP.

Question 13

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.